National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 33443 [E8-13150]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 114 / Thursday, June 12, 2008 / Notices
Contact Person: Thomas A. Tatham, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
§ 93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: June 5, 2008.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–13149 Filed 6–11–08; 8:45 am]
Dated: June 5, 2008.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–13150 Filed 6–11–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
mstockstill on PROD1PC66 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Planning Grant in
Life Style Interventions.
Date: July 16, 2008.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davilabloomm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; George M. O’Brien
Urology Research Centers (P50).
Date: July 21–22, 2008.
VerDate Aug<31>2005
21:47 Jun 11, 2008
Jkt 214001
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Crowne Plaza National Airport, 2650
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Paul A. Rushing, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Measures of Co-Occurring
Infrastructure (OMB No. 0930–0284)—
Revision
SAMHSA’s Center for Mental Health
Services and Center for Substance
Abuse Treatment conducts a data
collection activity for provider-level
performance measures about the
screening, assessment, and treatment of
co-occurring disorders. The measures
were developed with active input from
COSIG grantees. Their input was also
sought regarding suggestions for making
the implementation and reporting
processes as smooth as possible. Based
on suggestions from COSIG grantees,
CSAT has taken the following actions to
improve data quality: Clarified
instructions, simplified minimum
required reporting, developed optional
reporting methods, allowed grantees
time to work out internal processes, and
held monthly conference calls to answer
grantee questions and to allow grantees
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
33443
to share experiences with
implementation. These steps allow
CSAT to enhance working relationships
with the grantees and improve the
overall quality of the data collection
process.
Implementation will be limited to 16
of the States with Co-occurring State
Incentive Grants (COSIG) and States
receiving COSIG grants in future years.
COSIG grants enable States to develop
or enhance their infrastructure and
capacity to provide accessible, effective,
comprehensive, coordinated/integrated,
and evidence-based treatment services
to persons with co-occurring substance
abuse and mental disorders. Only the
immediate Office of the Governor of
States may receive COSIG grants,
because SAMHSA considers the Office
of the Governor to have the greatest
potential to provide the multi-agency
leadership needed to accomplish COSIG
goals. The COSIG program is part of
SAMHSA’s plan to achieve certain goals
regarding services for persons with cooccurring substance use and mental
disorders:
• Increase percentage of treatment
programs that screen for co-occurring
disorders;
• Increase percentage of treatment
programs that assess for co-occurring
disorders;
• Increase percentage of treatment
programs that treat co-occurring
disorders through collaborative,
consultative, and integrated models of
care;
• Increase the number of persons
with co-occurring disorders served.
These measures will enable SAMHSA
to benchmark and track progress toward
these goals within COSIG States.
Information will be collected annually
about the number and percentage of
programs that offer screening,
assessment, and treatment services for
co-occurring disorders; and the number
of clients actually screened, assessed,
and treated through these programs.
Information will also be collected
annually about providers’ policies
regarding screening, assessment, and
treatment services for persons with cooccurring disorders.
A questionnaire, to be completed by
providers, contains 47 items, answered
either by checking a box or entering a
number in a blank. The questionnaire is
available both in printed form and
electronically. Obtaining the
information to enter on the
questionnaire will require respondent
providers to track screening,
assessment, and treatment services for
clients.
COSIG States will be required to
report information to SAMHSA for all
E:\FR\FM\12JNN1.SGM
12JNN1
]]>Agencies
[Federal Register Volume 73, Number 114 (Thursday, June 12, 2008)]
[Notices]
[Page 33443]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-13150]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Planning Grant in Life
Style Interventions.
Date: July 16, 2008.
Time: 10 a.m. to 12 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Maria E. Davila-Bloom, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7637, davila-bloomm@extra.niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; George M. O'Brien
Urology Research Centers (P50).
Date: July 21-22, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Crowne Plaza National Airport, 2650 Jefferson Davis
Highway, Arlington, VA 22202.
Contact Person: Paul A. Rushing, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 747,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895,
rushingp@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: June 5, 2008.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-13150 Filed 6-11-08; 8:45 am]
BILLING CODE 4140-01-P
